Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16272281 | 0.88 | PDE4B (0.46) | PDE4BFDPSALDH1A1TSHRHPGD | |
| SCHEMBL16272280 | 0.86 | ALDH1A1 (0.45) | FDPSALDH1A1TSHRHPGDTDP1 | |
| SCHEMBL2843898 | 0.83 | ALDH1A1 (0.62) | PDE4BFDPSALDH1A1TSHRHPGD | |
| SCHEMBL2838672 | 0.83 | FDPS (0.67) | PDE4BFDPSALDH1A1TSHRHPGD | |
| SCHEMBL16272278 | 0.83 | PDE4B (0.45) | PDE4BFDPSALDH1A1TSHRHPGD | |
| SCHEMBL112198 | 0.80 | KDM4E (0.50) | PDE4BALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL29440158 | 0.79 | PDE4B (0.45) | PDE4BFDPSALDH1A1TSHRMAPT | |
| SCHEMBL141941 | 0.79 | PDE4B (0.45) | PDE4BFDPSALDH1A1TSHRMAPT | |
| SCHEMBL1121530 | 0.78 | ALDH1A1 (0.67) | FDPSALDH1A1TSHRHPGDTDP1 | |
| SCHEMBL29956585 | 0.78 | ALDH1A1 (0.67) | FDPSALDH1A1TSHRHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-12-04 | — | — | US | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | THE UNIVERSITY OF MELBOURNE (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | NFATC1, AADAC, NAT1 | PDE4B 1014/4885FDPS 681/4885ALDH1A1 201/4885 |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | PDE4B 1131/4885FDPS 399/4885ALDH1A1 242/4885 |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | PDE4B 1131/4885FDPS 399/4885ALDH1A1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.